On 12 Nov 2026 Revvity closed at $157.02, +62.7% this year; market cap $17.56bn, P/E 69.3.
Health Care · Health Care Equipment · NYSE · United States
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| Market cap | $17.56bn |
| P/E (trailing) | 69.3 |
| EPS (TTM) | $2.26 |
| Beta | 1.09 |
| Dividend | $0.28 |
| Dividend yield | 0.18% |
| Ex-dividend date | 22 Jan 2027 |
| Latest report | 3 Nov 2026 |
| Next earnings | 2 Feb 2027 |
| YTD | +62.7% |
| 1Y | +67.2% |
| 3Y | +23.5% |
| 5Y | -2.9% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $2.86bn | $241.68m | $508.25m |
| 2024 | $2.76bn | $295.83m | $541.65m |
| 2023 | $2.75bn | $-118.38m | $9.90m |
| 2022 | $3.31bn | $569.18m | $594.18m |
| 2021 | $3.83bn | $943.16m | $1.31bn |
We publish no single base value for Revvity. Our valuation methods put it between $80.26 and $89.40 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.